The high is wearing off for investors in cannabis stocks
Cannabis stocks were white-hot last year. But many North American pot firms have now lost two-thirds of their value.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
Legalisation in Canada and California meant that the cannabis sector was "white-hot" last year, says Kristine Owram on Bloomberg. Yet many North American pot firms have now "lost two-thirds... of their value". Canada's Canopy Growth Corporation, the world's largest, has reported poor sales.
The shares are down 47% so far this year. CEO Mark Zekulin told analysts that the "addressable market is only about half of what was originally expected", reports Ciara Linnane for MarketWatch. Cannabis retailer MedMen announced at the end of last week that it will cut "more than 20% of its staff" as it struggles with a cash crunch.
The industry faces several problems, says Owram. Efforts to legalise it in new markets have stalled, established black-market dealers are providing stiff competition and big institutional investors are sitting on the sidelines because the drug remains "federally illegal in the US". That leaves cannabis shares hostage to the whims of retail investors.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The market has become plagued by oversupply, adds Alexander Osipovich in The Wall Street Journal. Yet some analysts think that the recent falls are a buying opportunity. As more European and Latin American countries move towards legalising medicinal or recreational cannabis, the "long-term growth prospects" will still be tempting for some.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
UK interest rates live: rates held at 3.75%The Bank of England’s Monetary Policy Committee (MPC) met today to decide UK interest rates, and voted to hold rates at their current level
-
MoneyWeek Talks: The funds to choose in 2026Podcast Fidelity's Tom Stevenson reveals his top three funds for 2026 for your ISA or self-invested personal pension